Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1984 1
1985 1
1986 1
1987 2
1988 6
1989 9
1990 8
1991 15
1992 14
1993 33
1994 18
1995 12
1996 6
1997 3
1998 1
1999 2
2000 4
2001 1
2002 1
2003 1
2005 2
2014 1
2017 2
2018 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

146 results

Results by year

Filters applied: . Clear all
Page 1
Flosequinan.
Barnett DB. Barnett DB. Lancet. 1993 Mar 20;341(8847):733-6. doi: 10.1016/0140-6736(93)90498-6. Lancet. 1993. PMID: 8095635 Review. No abstract available.
Actions of the novel vasodilator, flosequinan, in isolated ventricular cardiomyocytes.
Kelso EJ, McDermott BJ, Silke B. Kelso EJ, et al. J Cardiovasc Pharmacol. 1995 Mar;25(3):376-86. doi: 10.1097/00005344-199503000-00005. J Cardiovasc Pharmacol. 1995. PMID: 7769801
We studied the interaction of flosequinan or the metabolite with other PDE inhibitors in rat cardiomyocytes. ...Flosequinan increased beating frequency in rat isolated right auricles concentration dependently and was significant over the concentration range of 10(-5 …
We studied the interaction of flosequinan or the metabolite with other PDE inhibitors in rat cardiomyocytes. ...Flosequinan in …
Tetralogy of Fallow: Four Trials and Tribulations.
Packer M. Packer M. JACC Heart Fail. 2017 Jun;5(6):408-410. doi: 10.1016/j.jchf.2017.03.004. Epub 2017 May 10. JACC Heart Fail. 2017. PMID: 28501525 Free article. No abstract available.
Long-Term Effects of Flosequinan on the Morbidity and Mortality of Patients With Severe Chronic Heart Failure: Primary Results of the PROFILE Trial After 24 Years.
Packer M, Pitt B, Rouleau JL, Swedberg K, DeMets DL, Fisher L. Packer M, et al. JACC Heart Fail. 2017 Jun;5(6):399-407. doi: 10.1016/j.jchf.2017.03.003. Epub 2017 May 10. JACC Heart Fail. 2017. PMID: 28501522 Free article. Clinical Trial.
OBJECTIVES: The purpose of this clinical trial was to evaluate the long-term effects of flosequinan on the morbidity and mortality of patients with severe chronic heart failure. ...Flosequinan also increased the risk of disease progression, which was paralleled by d …
OBJECTIVES: The purpose of this clinical trial was to evaluate the long-term effects of flosequinan on the morbidity and mortality of …
Effects of concurrent administration of flosequinan and digoxin on the pharmacokinetics of each drug.
Rau R, Hind ID, Wynne RD, White SA. Rau R, et al. Arzneimittelforschung. 1994 Mar;44(3):300-4. Arzneimittelforschung. 1994. PMID: 8192694
The pharmacokinetic and pharmacodynamic effects of co-administration of flosequinan (BTS 49465, CAS 76568-02-0) and digoxin (CAS 20830-75-5) were investigated in 12 healthy volunteers. ...No statistically significant differences were observed for any of the pharmacokinetic …
The pharmacokinetic and pharmacodynamic effects of co-administration of flosequinan (BTS 49465, CAS 76568-02-0) and digoxin (CAS 2083 …
Pharmacology of flosequinan.
Yates DB. Yates DB. Am Heart J. 1991 Mar;121(3 Pt 1):974-83. doi: 10.1016/0002-8703(91)90229-b. Am Heart J. 1991. PMID: 2000776 Review.
Flosequinan is a novel quinolone with cardiovascular activity that is likely to be of value in the treatment of both heart failure and hypertension. Data generated from animal studies indicate that flosequinan produces dilatation in both veins and arteries, with lit …
Flosequinan is a novel quinolone with cardiovascular activity that is likely to be of value in the treatment of both heart failure an …
Flosequinan in chronic heart failure: how is exercise capacity improved?
Banning AP, Ramsey MW, Jones EA, Evans W, Carolan G, Jones CH, Henderson AH. Banning AP, et al. Eur J Clin Pharmacol. 1996;51(2):133-8. doi: 10.1007/s002280050173. Eur J Clin Pharmacol. 1996. PMID: 8911877 Clinical Trial.
Brachial-radial pulse wave velocities were unaltered by flosequinan treatment. CONCLUSIONS: Our results confirm that flosequinan improves exercise duration in patients with chronic heart failure. ...This has resulted in the withdrawal of flosequinan from rout …
Brachial-radial pulse wave velocities were unaltered by flosequinan treatment. CONCLUSIONS: Our results confirm that flosequinan …
Stereoselective S-oxidation and reduction of flosequinan in rat.
Kashiyama E, Yokoi T, Odomi M, Kamataki T. Kashiyama E, et al. Xenobiotica. 1999 Aug;29(8):815-26. doi: 10.1080/004982599238263. Xenobiotica. 1999. PMID: 10553722
Cytosol from both the liver and kidney catalysed the reduction of R(+)-flosequinan (R-FSO) and S(-)-flosequinan (S-FSO) to flosequinan sulphide (FS, 7-fluoro-1-methyl-3-methylthio-4-quinolone). Flosequinan sulphone (FSO2, 7-fluoro-1-methyl-3-methylsulp …
Cytosol from both the liver and kidney catalysed the reduction of R(+)-flosequinan (R-FSO) and S(-)-flosequinan (S-FSO) to …
General pharmacological properties of the new vasodilator flosequinan.
Ikezono K, Fujita S, Umezato M, Hosoki E, Toba Y, Kusunoki A, Shintani S. Ikezono K, et al. Arzneimittelforschung. 1992 Oct;42(10):1200-11. Arzneimittelforschung. 1992. PMID: 1472141
The somatic nervous system: Flosequinan did not cause muscle relaxation in mice and had little effect on neuromuscular transmission in cats. ...Flosequinan does not seem to exert any on norepinephrine, serotonin, acetylcholine or histamine. ...
The somatic nervous system: Flosequinan did not cause muscle relaxation in mice and had little effect on neuromuscular transmission i …
Effects of low-dose flosequinan on left ventricular systolic and diastolic chamber performance.
Starling MR. Starling MR. Am Heart J. 1994 Jul;128(1):124-33. doi: 10.1016/0002-8703(94)90018-3. Am Heart J. 1994. PMID: 8017265 Free article.
Flosequinan (manoplax) is a new vasodilating agent for the treatment of congestive heart failure. ...Gated equilibrium radionuclide angiography was performed both before and during a steady-state infusion of flosequinan. The average flosequinan infusion rate …
Flosequinan (manoplax) is a new vasodilating agent for the treatment of congestive heart failure. ...Gated equilibrium radionuclide a …
146 results